Explore › Intervention › Sertraline monotherapy
Intervention

Sertraline monotherapy

Also known as: Sertraline monotherapy (up to 200mg/day, 8 medication management sessions over 12 weeks) in youth ages 7-17 with anxiety disorders AD SRT
3 findings 1 paper 4 related entities View in graph →

Related entities

conditions
Anxiety Disorders1
outcomes
youth anxiety symptoms1
populations
Children1
studys
PMC64257331

Findings (27)

None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →
None
improvement

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

Size: b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)
PMC6425733
Finding details → · Paper → · Graph →

Papers (1)